- Home
- PAMT vs BDTX Comparison
PAMT vs BDTX Comparison
Compare PAMT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- BDTX
- Stock Information
- Founded
- PAMT 1980
- BDTX 2014
- Country
- PAMT United States
- BDTX United States
- Employees
- PAMT N/A
- BDTX N/A
- Industry
- PAMT Trucking Freight/Courier Services
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAMT Industrials
- BDTX Health Care
- Exchange
- PAMT Nasdaq
- BDTX Nasdaq
- Market Cap
- PAMT 223.5M
- BDTX 220.3M
- IPO Year
- PAMT 1985
- BDTX 2020
- Fundamental
- Price
- PAMT $10.02
- BDTX $3.62
- Analyst Decision
- PAMT Hold
- BDTX Strong Buy
- Analyst Count
- PAMT 1
- BDTX 5
- Target Price
- PAMT $13.00
- BDTX $10.40
- AVG Volume (30 Days)
- PAMT 6.7K
- BDTX 795.1K
- Earning Date
- PAMT 10-28-2025
- BDTX 11-05-2025
- Dividend Yield
- PAMT N/A
- BDTX N/A
- EPS Growth
- PAMT N/A
- BDTX N/A
- EPS
- PAMT N/A
- BDTX 0.25
- Revenue
- PAMT $623,270,000.00
- BDTX $70,000,000.00
- Revenue This Year
- PAMT N/A
- BDTX N/A
- Revenue Next Year
- PAMT $12.19
- BDTX N/A
- P/E Ratio
- PAMT N/A
- BDTX $14.46
- Revenue Growth
- PAMT N/A
- BDTX N/A
- 52 Week Low
- PAMT $9.68
- BDTX $1.20
- 52 Week High
- PAMT $23.70
- BDTX $4.45
- Technical
- Relative Strength Index (RSI)
- PAMT 31.08
- BDTX 44.71
- Support Level
- PAMT $9.68
- BDTX $3.71
- Resistance Level
- PAMT $11.12
- BDTX $3.97
- Average True Range (ATR)
- PAMT 0.41
- BDTX 0.23
- MACD
- PAMT -0.09
- BDTX -0.06
- Stochastic Oscillator
- PAMT 16.83
- BDTX 0.00
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.